Wedbush Reaffirms “Outperform” Rating for Oculis (NASDAQ:OCS)

Wedbush restated their outperform rating on shares of Oculis (NASDAQ:OCS) in a report issued on Friday morning, Benzinga reports. They currently have a $29.00 target price on the stock.

Several other equities research analysts have also issued reports on OCS. HC Wainwright reiterated a buy rating and issued a $29.00 price target on shares of Oculis in a research note on Wednesday, August 30th. Robert W. Baird boosted their price target on Oculis from $58.00 to $64.00 in a research report on Wednesday, August 9th. Stifel Nicolaus initiated coverage on Oculis in a report on Wednesday, October 4th. They issued a buy rating and a $35.00 price objective for the company. Finally, Bank of America boosted their target price on shares of Oculis from $23.00 to $24.00 and gave the stock a buy rating in a report on Tuesday, August 29th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus target price of $34.00.

Oculis Trading Down 1.1 %

Shares of Oculis stock opened at $9.60 on Friday. Oculis has a twelve month low of $6.26 and a twelve month high of $14.50. The firm’s 50-day simple moving average is $10.66 and its 200-day simple moving average is $11.72.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, August 29th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The business had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.28 million. On average, equities analysts forecast that Oculis will post -2.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC acquired a new position in shares of Oculis during the second quarter valued at about $44,000. Wolverine Asset Management LLC bought a new stake in Oculis during the 3rd quarter worth approximately $77,000. HRT Financial LP purchased a new stake in shares of Oculis in the first quarter worth approximately $178,000. Ergoteles LLC bought a new position in shares of Oculis in the second quarter valued at approximately $247,000. Finally, Nan Fung Group Holdings Ltd purchased a new position in shares of Oculis during the first quarter valued at approximately $4,838,000. Institutional investors and hedge funds own 14.28% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.